Werdnig Hoffmann Disease


Continuing Education Activity

Werdnig-Hoffmann disease is a type of spinal muscular atrophy (SMA). It is the most common type of SMA and accounts for about 80% of individuals with this condition. This is the most severe form of spinal muscular atrophy, and infants with this condition experience severe muscle weakness with onset before 6 months of age, and presenting symptoms include severe motor weakness, poor muscle tone, and lack of motor development. This activity reviews the evaluation and management of Werdnig-Hoffmann disease and highlights the role of the interprofessional team in evaluating and treating patients with this condition.

Objectives:

  • Identify the etiology of Werdnig-Hoffmann disease.
  • Review the appropriate evaluation of Werdnig-Hoffmann disease.
  • Outline the management options available for Werdnig-Hoffmann disease.
  • Describe interprofessional team strategies for improving care coordination and communication to advance Werdnig-Hoffmann disease and improve outcomes.

Introduction

Werdnig-Hoffmann disease is a type of spinal muscular atrophy (SMA), a rare form of motor neuron disease. It is the most common type of SMA and accounts for about 80% of individuals with this condition. There are 4 types of SMA, Werdnig-Hoffmann disease, also known as SMA1 is the most severe form, and infants with this condition experience severe muscle weakness with onset before 6 months of age and presenting symptoms include severe motor weakness, poor muscle tone and lack of motor development.

Motor neuron disease is a condition that affects anterior horn cells of the motor neurons.[1] These are the neurons that control voluntary muscle control. These are rare conditions that are often very severe, and no cure is available. Examples of motor neuron diseases include amyotrophic lateral sclerosis (ALS), progressive muscular atrophy (PMA), SMA, progressive bulbar palsy (PBP), primary lateral sclerosis (PLS), etc., These conditions spare sensory nerves and individuals do not have sensory involvement. Individuals often have a combination of upper and lower motor neuron symptoms.

SMA is a type of motor neuron disease. SMA presents four subtypes.[2]

  • Werdnig-Hoffmann disease, also known as acute spinal muscular atrophy, is SMA 1.
  • SMA2, also known as intermediate SMA and chronic infantile SMA, have less severe symptoms than SMA1 and can sit without support, but are unable to stand or walk. SMA2 symptom onset is in infanthood.
  • SMA3, also known as Kugelberg-Welander disease, presents after the age of 1, and the child is able to walk initially, but later has the regression of motor abilities. They often develop poor balance, falls, and scoliosis.
  • Individuals with SMA4 have minimal symptoms compared to the other forms, and symptom onset is after the age of 10 years. They usually have a normal lifespan. They usually have normal motor milestones and mobility.

Etiology

Werdnig-Hoffmann disease is acquired in an autosomal recessive fashion. Abnormality is noted in the survival motor neuron (SMN) gene. 2 SMN genes have been identified. Both these genes are located on chromosome 5. SMN1 gene is located at locus 5q11-q13. SMN2 is located next to the SMN1 gene. SMN1 is believed to cause SMA, while SMN2 is believed to affect the severity of the disease; higher SMN2 copies result in a milder form of SMA. In addition, other genetic mutations have been identified to play a role in the severity of SMA. 1, and such identified mutation is the deletion of neuronal apoptosis inhibitory protein (NAIP) gene.[3][4]

Epidemiology

Werdnig-Hoffmann disease affects about one in every 10,000 live births.[5] It is the second most common autosomal recessive disorder. It can affect men and women equally. About 50% of individuals die prior to birth. Age at presentation is always prior to 6 months of age.

Pathophysiology

Werdnig-Hoffmann disease is a motor neuron disease in which there is anterior horn cell degeneration of the spinal cord. In utero, there is an excess of motor neuroblasts with only half surviving until birth. After birth, the disease is progressive with continued loss of motor neurons in the spinal cord and brainstem.[2]

History and Physical

The majority of infants present at birth with severe weakness and wasting of the limbs. These infants have difficulty with swallowing and respiratory muscles. Other brain stem muscles also become involved, including the bulbar muscles. The distinctive feature of Werdnig-Hoffmann disease is that these individuals do not have any evidence of cerebral or higher central nervous system dysfunction. They have normal intelligence and demonstrate a keen sense of learning. Hypotonia is a very profound and classical finding. Deep tendon reflexes are absent diffusely. Hypermobility of the joints is noted secondary to poor muscle tone. The twitching of muscles of the tongue (fasciculations) is noted. Tongue fasciculations are classical findings seen in motor neuron diseases and are also seen in other motor neuron diseases like amyotrophic lateral sclerosis, etc. The child does not gain head control and is unable to sit, stand, or walk. They often have difficulties with swallowing and breathing. They have a poor sucking reflex. They have a high risk of aspiration pneumonia due to weak bulbar muscles. For infants in whom the symptoms develop after birth, motor regression occurs, and there appears to be greater involvement of lower extremities compared to upper extremities. Muscles controlling extraocular movements are generally spared.[6][7]

Evaluation

The diagnosis of Werdnig-Hoffmann disease is made after a detailed clinical history and physical exam. A family history of the disease is highly suggestive of the disorder. Genetic tests are available prenatally and postnatally for a definitive diagnosis. Prenatally, chorionic villus sampling or amniocentesis can be done to obtain tissues for genetic testing.[8][9]

Molecular genetic testing is available and tests for the SMN gene, Werdnig-Hoffmann disease is caused by partial or complete loss of SMN gene. Electromyography (EMG) testing can be helpful in identifying myopathic potentials, but due to the widespread availability of genetic testing, it is no longer used in the diagnosis of this condition.

Treatment / Management

There is no cure for Werdnig-Hoffmann disease.

Nusinersen is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide, and FDA approved for the treatment of SMA in adult and pediatric patients. It is administered intrathecally. It increases exon 7 inclusion in SMN2 messenger ribonucleic acid (mRNA) and assists in the production of full-length SMN protein.[10]

The treatment is supportive. Medications that are often used to improve symptoms include phenylbutyrate, valproic acid, albuterol, and hydroxyurea. Unfortunately, clinical trials have not shown any definite evidence that these medications prevent the progression of the disease. Treatment is directed towards symptom control. Symptomatic treatment is aimed at support with feeding, breathing, and motor weakness.[7]

Feeding difficulties: Children often have difficulty with feeding and can have nutritional deficiencies or aspiration pneumonia secondary to swallowing difficulty. Percutaneous endoscopic gastrostomy (PEG) tubes can help with nutritional supplementation.

Respiratory difficulties: Children may require non-invasive ventilator support initially as respiratory muscles are involved. As symptoms worsen, they may need tracheostomy and ventilator support.

Motor weakness: Physical and occupational therapy can help with muscle stretching, strengthening, and minimizing contractures. Surgical procedures to help with scoliosis and braces may be helpful.

Differential Diagnosis

  • Prader-Willi syndrome: Hypotonia, short stature, mental retardation, developmental delay, cognitive delay, hypersomnia, multiple endocrine abnormalities, hypogonadism, temperature instability, and central adrenal insufficiency.[11]
  • Congenital myasthenia gravis: caused by a mutation in an AChR subunit gene. It presents with fatigable weakness involving the ocular and cranial muscles.[12]
  • Congenital myopathies: Slowly progressive muscle disease presenting with muscle weakness with hypotonia.[13] 
  • Infantile Pompe disease: Muscle disease presenting with hypotonia, hearing problems, failure to thrive, and cardiac muscle involvement.[14]
  • Congenital muscular dystrophy (CMD): Individuals present with hypotonia, contractures, delay of motor milestones. 
  • Arthrogryposis multiplex congenita: Individuals develop multiple joint contractures. 
  • Adrenoleukodystrophy: Individuals present with seizures, trouble swallowing, hearing loss, and cognitive impairment.

Prognosis

The prognosis for Werdnig Hoffmann disease is very poor. The disease presents before 6 months of age, and it is a progressive muscular disorder that often results in early death. Most patients die prematurely either in infancy or early childhood, often by 2 years of life. This is the most common genetic cause of infant mortality.[7]

Complications

  • Orthopedic complications are common secondary to hypotonia, muscle weakness, and wasting. Scoliosis, joint contractures, ankylosis are seen often. Physical and occupational therapy, orthopedic surgery, and braces can help with the management of these symptoms.
  • Aspiration pneumonia may occur secondary to bulbar weakness.
  • Malnutrition is a common complication secondary to swallowing difficulty.

Deterrence and Patient Education

The diagnosis of Werdnig-Hoffmann disease can be stressful and overwhelming for the families. Patient education must be an important part of the clinical management of patients with this condition. Counseling must be given about prognosis, complications, and outcomes. Support groups can help with the management of issues like anxiety, frustration, loneliness, and depression. The patient’s families should be counseled about the diagnosis and the prognosis. Clinicians and family members should also establish medical and psychosocial treatment plans.

Enhancing Healthcare Team Outcomes

Werdnig-Hoffmann disease is a rare condition and presents with severe symptoms in an infant. An interprofessional approach is recommended when managing patients with this condition. The presentation of this disease is complex, and a need for prompt diagnosis and initiation of treatment is imperative. This is best achieved by care coordination and interprofessional communication between pediatricians, pediatric neurologists, nurses, pharmacists, physical and occupational therapists. This can help also reduce hospitalization and decrease emergency department visits. Caring for patients with Werdnig-Hoffmann disease is complex and requires extensive interprofessional communication to improve patient outcomes.


Article Details

Article Author

Prabhu Emmady

Article Editor:

Jeffrey Bodle

Updated:

12/12/2020 7:10:42 PM

References

[1]

McDermott CJ,Shaw PJ, Diagnosis and management of motor neurone disease. BMJ (Clinical research ed.). 2008 Mar 22;     [PubMed PMID: 18356234]

[2]

Shababi M,Lorson CL,Rudnik-Schöneborn SS, Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease? Journal of anatomy. 2014 Jan;     [PubMed PMID: 23876144]

[3]

Farrar MA,Kiernan MC, The Genetics of Spinal Muscular Atrophy: Progress and Challenges. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2015 Apr;     [PubMed PMID: 25413156]

[4]

Sedghi M,Behnam M,Fazel E,Salehi M,Ganji H,Meamar R,Hosseinzadeh M,Nouri N, Genotype-phenotype correlation of survival motor neuron and neuronal apoptosis inhibitory protein genes in spinal muscular atrophy patients from Iran. Advanced biomedical research. 2014;     [PubMed PMID: 24627882]

[5]

Verhaart IEC,Robertson A,Wilson IJ,Aartsma-Rus A,Cameron S,Jones CC,Cook SF,Lochmüller H, Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet journal of rare diseases. 2017 Jul 4;     [PubMed PMID: 28676062]

[6]

D'Amico A,Mercuri E,Tiziano FD,Bertini E, Spinal muscular atrophy. Orphanet journal of rare diseases. 2011 Nov 2;     [PubMed PMID: 22047105]

[7]

Kolb SJ,Kissel JT, Spinal Muscular Atrophy. Neurologic clinics. 2015 Nov;     [PubMed PMID: 26515624]

[8]

Khaniani MS,Derakhshan SM,Abasalizadeh S, Prenatal diagnosis of spinal muscular atrophy: clinical experience and molecular genetics of SMN gene analysis in 36 cases. Journal of prenatal medicine. 2013 Jul;     [PubMed PMID: 24175014]

[9]

Harding BN,Kariya S,Monani UR,Chung WK,Benton M,Yum SW,Tennekoon G,Finkel RS, Spectrum of neuropathophysiology in spinal muscular atrophy type I. Journal of neuropathology and experimental neurology. 2015 Jan;     [PubMed PMID: 25470343]

[10]

Neil EE,Bisaccia EK, Nusinersen: A Novel Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG. 2019 May-Jun;     [PubMed PMID: 31093018]

[11]

Angulo MA,Butler MG,Cataletto ME, Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. Journal of endocrinological investigation. 2015 Dec;     [PubMed PMID: 26062517]

[12]

Engel AG,Shen XM,Selcen D,Sine SM, Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. The Lancet. Neurology. 2015 Apr;     [PubMed PMID: 25792100]

[13]

Cassandrini D,Trovato R,Rubegni A,Lenzi S,Fiorillo C,Baldacci J,Minetti C,Astrea G,Bruno C,Santorelli FM, Congenital myopathies: clinical phenotypes and new diagnostic tools. Italian journal of pediatrics. 2017 Nov 15;     [PubMed PMID: 29141652]

[14]

Kishnani PS,Steiner RD,Bali D,Berger K,Byrne BJ,Case LE,Crowley JF,Downs S,Howell RR,Kravitz RM,Mackey J,Marsden D,Martins AM,Millington DS,Nicolino M,O'Grady G,Patterson MC,Rapoport DM,Slonim A,Spencer CT,Tifft CJ,Watson MS, Pompe disease diagnosis and management guideline. Genetics in medicine : official journal of the American College of Medical Genetics. 2006 May;     [PubMed PMID: 16702877]